Tumor immunophenotype was characterized by a strong expression of conventional myeloid antigens (CD13, CD33, CD15, MPO), although no monocytic (CD14, CD64, CD11c, CD11b, lysozyme), megakaryoblastic (CD61, CD41) and lymphoid (CD7, CD19, iCD79a, CD56, CD2) markers were found. Here, CD2 is linked to neoplasm.